MedTrace Logo

Study of TAVO103A in Healthy Volunteers

NCT05313152 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-12-12

No results posted yet for this study

Summary

This is a Phase 1, single ascending dose study designed to investigate TAVO103A, administered as an IV infusion up to 60 minutes in length to healthy adult subjects. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAVO103A.

Conditions

  • Healthy Subjects

Interventions

DRUG

TAVO103A

TAVO103A single ascending dose IV infusion.

OTHER

Placebo

Placebo single ascending dose IV infusion.

Sponsors & Collaborators

  • Tavotek Biotherapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-05
Primary Completion
2023-04-26
Completion
2023-06-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05313152 on ClinicalTrials.gov